Abstract
The studies recommended the relationship between lots of polymorphisms with the head and neck cancers (HNCs) risk. Herein, we reported the association between the CYP1A1 MspI polymorphism and the risk of HNC in an updated meta-analysis. The PubMed/MEDLINE, Web of Science, Cochrane Library, and Scopus databases were searched until March 31, 2021, without any restrictions. Odds ratios (ORs) and 95% confidence intervals (CIs) were applied to assess a relationship between CYP1A1 MspI polymorphism and the HNC risk based on five applied genetic models by RevMan 5.3 software. Other analyses (sensitivity analysis, meta-regression, and bias analysis) were performed by CMA 2.0 software. Trial sequential analysis (TSA) was done by TSA software (version 0.9.5.10 beta). Among the databases and other sources, 501 recorded were identified that at last, 29 studies were obtained for the analysis. The pooled ORs were 1.28 (95%CI 1.09, 1.51; P = 0.003), 1.68 (95%CI 1.16, 2.45; P = 0.007), 1.24 (95%CI 1.03, 1.50; P = 0.02), 1.26 (95%CI 1.07, 1.48; P = 0.005), and 1.66 (95%CI 1.27, 2.16; P = 0.0002) for allelic, homozygous, heterozygous, recessive, and dominant models, respectively. Therefore, the m2 allele and m1/m2 and m2/m2 genotypes had significantly increased risks in HNC patients. With regards to stable results and enough samples, the findings of the present meta-analysis recommended that there was an association between CYP1A1 MspI polymorphism and the HNC risk.
Highlights
The studies recommended the relationship between lots of polymorphisms with the head and neck cancers (HNCs) risk
Cytochrome P450 (CYP) enzymes perform a major role in the metabolic activation of polycyclic aromatic hydrocarbons (PAHs) to epoxide intermediates, suggesting a link between PAHs, the CYP pathway, and cancer development that cytochrome P450 1A1 (CYP1A1) is believed to be the most important enzyme in this link[16] and CYP1A1, as a drug-metabolizing enzyme, is among the main enzymes imported in the processing of tobacco-related carcinogens[17]
57 articles excluded with reasons (one mixed oral precancerous and cancer cases, one had no control group, two reviews, four reported CYP1A1 expression, two didn’t report the prevalence of alleles and genotypes, one book chapter, twenty-two reported other polymorphisms of CYP1A1, two reported duplicate publications, one family-based study, one had no sufficient data, one reported oral precancerous cases, twelve studies reported less than 100 cases in one or two groups, and seven meta-analyses)
Summary
The studies recommended the relationship between lots of polymorphisms with the head and neck cancers (HNCs) risk. Odds ratios (ORs) and 95% confidence intervals (CIs) were applied to assess a relationship between CYP1A1 MspI polymorphism and the HNC risk based on five applied genetic models by RevMan 5.3 software. Abbreviations HNC Head and neck cancer CYP Cytochrome P450 OR Odds ratio CI Confidence interval PAH Polycyclic aromatic hydrocarbon TSA Trial sequential analysis GST Glutathione-S-transferase. Genetic elements have been implicated in the pathogenesis of this cancer In support of this statement, several recent meta-analyses have confirmed the relationship of various polymorphisms with the risk of H NC6–11. In comparison with our study and other meta-analyses, this meta-analysis included thyroid cancer and different sites of head and neck as HNC, apart from that oral cavity, larynx, and pharynx. We aimed to evaluate the connection between the polymorphism of CYP1A1 MspI and the risk of HNC with twenty-nine studies in a meta-analysis, meta-regression, and TSA
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
